期刊文献+

索非布韦的合成工艺改进 被引量:4

Synthesis and process optimization of sofosbuvir
下载PDF
导出
摘要 目的对索非布韦进行合成工艺改进以提高其收率。方法以(2'R)-N-苯甲酰基-2'-脱氧-2'-氟-2'-甲基胞苷-3',5'-二苯甲酸酯(6)为起始原料,于弱酸条件下选择性脱去氮上的保护基,碱性条件下脱去氧上的苯甲酰基,制得关键中间体(2'R)-2'-脱氧-2'-氟-2'-甲基脲苷(8);以L-丙氨酸异丙酯盐酸盐、二氯磷酸苯酯和五氟苯酚为原料合成稳定的磷酰胺试剂(5);磷酰胺试剂选择性对中间体8的5'位羟基进行亲核取代反应得终产物索非布韦。结果与讨论通过1H-NM R、13C-NM R、M S、IR及mp对索非布韦进行了结构确证,HPLC检测质量分数达99.6%,以原料6计算,总收率为14.97%。 Objective To improve the synthesis process of sofosbuvir for higher yield. Methods Using( 2'R)-N-benzoyl-2'-deoxy-2'-fluoro-2'-methylcytidine 3',5'-benzoate( 6) as starting material,the key intermediate( 2'R)-2'-deoxy-2'-fluoro-2'-methyluridine( 8) was obtained by deprotecting of benzoyl under acetic acidand ammonia conditions. Stable phosphoramidatin greagent( 5) was prepared by using L-alanine isopropyl ester hydrochloride,dichloro-phenyl phosphate and pentafluorophenol as materials of synthesis. Sofosbuvir could be obtained through selective nucleophilic displacement of 5'-hydroxyl group of nucleosides( 8). Results and Conclusions Sofosbuvir was synthesizedwith total yield of 14. 97%( based on the fed amount of compound 6 at the beginning) and with the purity of 99. 6%. The structure of sofosbuvir was confirmed by the using of techniques including1H-NMR,13C-NMR,MS,IR,and melting point determination.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2016年第5期355-357,363,共4页 Journal of Shenyang Pharmaceutical University
基金 国家基础科学人才培养基金资助项目(J1103606)
关键词 索非布韦 抗丙肝药物 工艺改进 sofosbuvir hepatitis C improved synthesis
  • 相关文献

参考文献5

  • 1陈本川.抗丙型肝炎病毒药:索氟布韦(sofosbuvir)[J].医药导报,2014,33(8):1118-1120. 被引量:10
  • 2GEOFFREY D,TABINAD B.Hepatitis C treatment:interferon free or interferon freer?[J].Lancet,2013,381(9883):2063-2065.
  • 3ROSS B S,REDDY P G,ZHANG H R,et al.Synthesis of diastereomerically pure nucleotide phosphoramidates[J].Journal of Organic Chemistry,2011,76(20):8311-8319.
  • 4ROSS B S,SOFIAM J,PAMULAPATI G R,et al.Stereoselective synthesis of phosphorous containing actices:2011123668A2[P].2010-03-31.
  • 5MOUSSA A M,MAYES B A,DOUSSON C B,et al.D-alanine ester of Rp-nucleoside analog:2014078427A1[P].2013-11-13.

二级参考文献4

  • 1FDA . SOFOSBUVIR [ EB/OL ]. [ 2013 - 12 - 06 ]. http :// www. accessdata, fda. gov/drugsatfda_ docs/label/2013/ 204671 s0001bl, pdf.
  • 2Carlota Reviriego GS-7977 [ J ]. Drugs Future ,2012,37 ( 3 ) : 175-182.
  • 3BRADLEY VINCE, JOHN M H, ERIC J L, et al. A random ized, double-blind, multiple-dose study of the pan-genotypie NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1,2,3 or 4 [J]. J Hepatol,2014,60(5) : 920-927.
  • 4KEATING, GILLIAN M. Vaidya, Asha Sofosbuvir : First Glo- bal Approval [ J]. Drugs,2014,74(2) :273-282.

共引文献9

同被引文献15

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部